DiaSys Corporation Presents Additional Patent Claims for Unique In Vitro Assay Technology to Detect and Monitor Kidney Failure or Malfunction.Business Editors/Health/Medical Writers WATERBURY, Conn.--(BUSINESS WIRE)--May 26, 2004 DiaSys Corporation(AMEX AMEX See: American Stock Exchange :DYX DYX Dyslexia ): Additional Claim to Include Home Testing Device DiaSys Corporation (AMEX: DYX) a global healthcare products company announced that it presented additional patent claims for it's unique in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. assay technology to detect and monitor kidney disease Kidney Disease Definition Kidney disease is a general term for any damage that reduces the functioning of the kidney. Kidney disease is also called renal disease. . Kidney malfunction may go undetected by current methods of testing until 80% or more of the kidney is damaged. The technology is quick, easy to use and inexpensive, providing front-line testing for early detection before the kidney degenerates or fails. The claims include monitoring, screening and adjunctive testing for renal (kidney) insufficiency and renal (kidney) failure due to diabetes, hypertension and monoclonal gammopathies. DiaSys Corporation has also presented an additional device claim to include a home testing configuration of its technology. Gregory Witchel, Chief Executive Officer of DiaSys Corporation said, " This technology will be able to detect a problem earlier than current methods, improving the patient's chances to avoid kidney damage kidney damage Kidney injury Nephrology A structural or functional compromise in renal function due to external–eg, athletic, occupational, or other trauma, resulting in bruising or hemorrhage, which can be profuse and life threatening Etiology Vascular and failure. The discovery of this application of our technology can affect patients of diabetes, hypertension and monoclonal gammopathies. Early detection and monitoring of kidney disease resulting from diabetes, hypertension or monoclonal gammopathies, can improve the quality of care for a large and growing number of patients. In the United States there is a need to monitor over 400,000 patients diagnosed each year with these conditions. The number of patients who are screened each year who can benefit from early detection using the company's technology are over 90 million." DiaSys Corporation projects total market revenue potential for monitoring these three disease states in the United States to be over $300 million annually. Projected total market screening revenues excluding the home and adjunctive testing markets are projected at over $600 million in the U.S. Those screened for PAP, PSA (Professional Services Automation) An information system designed to organize, track and manage all opportunities, work, resources, costs, revenues and invoices to improve the productivity and efficiency of the workforce. , MG and hypertension can use this technology as an additional test to detect kidney malfunction or failure. DiaSys Europe is currently assessing the patient populations for these three disease states in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community , including new member countries admitted May 1, 2004. New member countries add 75 million people to the EU bringing the total population of European Community members to 455 million people. DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion